Paper: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial
Program: Oral and Poster Abstracts Type: Oral Session: 655. Multiple Myeloma: Cellular Therapies: Unleashing Cell Therapies Against Myeloma Hematology Disease Topics & Pathways: Research, Clinical trials, Adult, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Study Population, Human Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP 1, Binod Dhakal, MBBS 2, Gurbakhash Kaur, MD, MA 3,
